Metabolic effects of inhibiting glucosylceramide synthesis with PDMP and other substances.
Radin
N S
NS
Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor 48109.
Shayman
J A
JA
Inokuchi
J
J
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002240:Carbohydrate Sequence; D002462:Cell Membrane / Q000378:metabolism; D005963:Glucosylceramides / Q000096:biosynthesis*; D005964:Glucosyltransferases / Q000037:antagonists & inhibitors*; D006801:Humans; D008969:Molecular Sequence Data; D009025:Morpholines / Q000494:pharmacology*; D010743:Phospholipids / Q000378:metabolism
D000970:Antineoplastic Agents; D005963:Glucosylceramides; D009025:Morpholines; D010743:Phospholipids; C033110:RV 538; D005964:Glucosyltransferases; C023246:ceramide glucosyltransferase